<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842630</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1916-I-101</org_study_id>
    <nct_id>NCT04842630</nct_id>
  </id_info>
  <brief_title>A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors</brief_title>
  <official_title>An Open-Label, Multicenter, Dose Escalation And Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in human, open-label, dose escalation and expansion Phase 1 study of SHR-1916&#xD;
      in adult patients with locally advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limited Toxicity (DLT)</measure>
    <time_frame>21 Days (first cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerable dose (MTD)</measure>
    <time_frame>21 Days (first cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose for phase II (RP2D)</measure>
    <time_frame>Up to 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs （Adverse Events）</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve in the dosing interval AUC(TAU) of SHR-1916</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of SHR-1916</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed plasma concentration (Cmin) of SHR-1916</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of SHR-1916</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of NK cell and CD8+ T cell by flow cytometry</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute count values of NK cell and CD8+ T cell by flow cytometry</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral plasma concentration of sCD25</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity analysis to assess anti-drug antibodies (ADA) to SHR-1916 in human serum</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR（Objective Response Rate）</measure>
    <time_frame>at the time point of every 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR（Disease Control Rate）</measure>
    <time_frame>at the time point of every 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR（Duration of Response）</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS（Progression-Free-Survival）</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month-survival Rate</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>SHR-1916</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1916</intervention_name>
    <description>All participants receive SHR-1906 alone</description>
    <arm_group_label>SHR-1916</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and the willingness to sign a written informed consent document；&#xD;
&#xD;
          2. Aged between 18-75 years old;&#xD;
&#xD;
          3. Histologically or cytologically confirmed advanced or metastatic malignant tumor;&#xD;
&#xD;
          4. Presence of at least of one measurable lesion in agreement to RECIST criteria;&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1;&#xD;
&#xD;
          6. Life expectancy &gt;12 weeks;&#xD;
&#xD;
          7. Adequate organ performance based on laboratory blood tests;&#xD;
&#xD;
          8. Women of childbearing potential and men must agree to use adequate contraception prior&#xD;
             to study entry and for the duration of study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received cytokines (IL-2, IFN-α)as anti-tumor therapy within 6&#xD;
             months before the first dose;&#xD;
&#xD;
          2. Previous systemic therapy within 28 days before the first dose;&#xD;
&#xD;
          3. Previous therapeutic surgery within 28 days, and diagnostic surgery within 14 days&#xD;
             prior to the first dose;&#xD;
&#xD;
          4. Received live attenuated vaccine within 28 days before the first dose, or expected to&#xD;
             receive live attenuated vaccine during the study treatment period;&#xD;
&#xD;
          5. Patients who received systemic immunosuppressive therapy within 14 days before the&#xD;
             first dose;&#xD;
&#xD;
          6. Patients with known or suspected brain metastasis；&#xD;
&#xD;
          7. Patients with interstitial pneumonia or interstitial lung disease, or history of&#xD;
             interstitial pneumonia or interstitial lung disease requiring hormone therapy, or&#xD;
             other pneumonia history that may interfere with the judgment of immune related&#xD;
             pulmonary toxicity, or chest CT scan found any evidence of active pneumonia;&#xD;
&#xD;
          8. Patients with history of autoimmune diseases;&#xD;
&#xD;
          9. History of immunodeficiency (including HIV infection) or organ transplantation;&#xD;
&#xD;
         10. Known active hepatitis B or C infection;&#xD;
&#xD;
         11. Other serious accompanying illnesses, which, in the researcher's opinion, could&#xD;
             seriously adversely affect the safety of the treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Cao, M.M</last_name>
    <phone>+0518-81220121</phone>
    <email>caoyong@hrs.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo, Doctor</last_name>
      <phone>010-88121122</phone>
      <email>Guoj307@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

